Morrison Foerster and Bayer Co.Lab are partnering to offer legal programming and support to the next generation of cell and gene therapy (CGT) startups. Bayer Co.Lab is a growing global network of life science incubators that provides entrepreneurs and early-stage companies access to state-of-the-art facilities, resources, and expertise. Their U.S. flagship site, Co.Lab Cambridge, is uniquely tailored to support the needs of cutting-edge CGT startups.
As a trusted partner to some of the leading innovators in the CGT sector, we are thrilled to partner with Bayer Co.Lab and their growing startup cohort. For decades, MoFo has been passionate about driving the success of pioneering life sciences companies at every stage of their evolution, from initial formation and venture capital financing through a sale or initial public offering. Our cross disciplinary team develops innovative legal, regulatory, and business strategies to help CGT companies overcome challenges along their path to market. Leveraging our market-leading life sciences capabilities in Boston and Berlin, we look forward to collaborating with Co.Lab’s residents as the organization continues to expand in these markets.
On September 14, MoFo and Co.Lab kicked-off this partnership with an “End-of-Summer” networking reception at the Co.Lab Cambridge facility. The event began with welcome remarks from Fiona Mack, Vice President and Head of Bayer Co.Lab Cambridge US, and MoFo Partners Matt Karlyn and Wolfgang Schoenig. The rest of the evening featured networking with guests from across the Cambridge cell and gene therapy innovation ecosystem, including MoFo's Life Sciences group, Co-Lab residents, investors, and strategic partners. As our partnership continues to develop, we look forward to providing Co.Lab residents with additional content from our team including seminars, office hours, and special access to MoFo programming.